CBLI Stock - Cytocom, Inc.
Unlock GoAI Insights for CBLI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $262,942 | $1.11M | $1.14M | $1.95M | $3.52M |
| Gross Profit | $262,942 | $1.11M | $1.14M | $1.95M | $3.52M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-2,586,551 | $-2,360,836 | $-4,799,906 | $-5,600,810 | $-6,355,850 |
| Net Income | $-2,398,457 | $-2,646,987 | $-3,611,973 | $-9,706,456 | $-2,658,865 |
| Net Margin | -912.2% | -237.7% | -317.3% | -498.2% | -75.6% |
| EPS | $-0.19 | $-0.23 | $-0.32 | $-0.87 | $-0.24 |
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Visit WebsiteEarnings History & Surprises
CBLIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2021 | Aug 16, 2021 | — | $-0.04 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.04 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.06 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.03 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.05 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.06 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.04 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.05 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.08 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.04 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.10 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.08 | — | — |
Q1 2018 | Mar 6, 2018 | — | $-0.11 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.10 | — | — |
Q4 2017 | Nov 14, 2017 | — | $-0.11 | — | — |
Q3 2017 | Aug 14, 2017 | — | $-0.50 | — | — |
Q2 2017 | May 15, 2017 | — | $-0.15 | — | — |
Q1 2017 | Feb 22, 2017 | — | $-0.11 | — | — |
Q4 2016 | Nov 14, 2016 | — | $0.10 | — | — |
Latest News
Frequently Asked Questions about CBLI
What is CBLI's current stock price?
What is the analyst price target for CBLI?
What sector is Cytocom, Inc. in?
What is CBLI's market cap?
Does CBLI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CBLI for comparison